UNSPSC 51182706: Metformin/repaglinide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182706 Metformin/repaglinide is a Commodity code that in practice captures procurement of specific pharmaceutical products and related medical supplies by state and local health authorities. Recent state and local opportunities tagged under this code show minimal alignment with the nominal pharmaceutical compound; instead, the code appears to capture broader health-department and county-level procurement of critical medical supplies and pharmacy program design. The issuing bodies include county health departments and state health and human services commissions pursuing both direct product acquisition and systemic pharmacy benefit initiatives. Scope of work ranges from routine procurement of high-volume emergency medical supplies—naloxone kits and drug deactivation systems for community health support—to exploratory contracting for direct-to-manufacturer pharmacy programs that bypass traditional pharmacy benefit managers and group purchasing organizations.

Activity is concentrated in the Southeast and Texas. Seminole County, Florida released an IFB (solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and contract terms including a two-year initial period plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information about vendors' capacity to establish direct contracts with self-insured employee group health plans and state agencies, negotiate net pricing models without rebates, and implement value-based agreements. The RFI is exploratory and does not specify budget ranges, set-asides, or formal award timelines; it precedes a formal RFP. Both opportunities require E-Verify compliance and federal regulatory adherence when funding permits; neither specifies disadvantaged-enterprise set-asides.